← Back to Portfolio

Wilson Therapeutics

Wilson is developing a novel de-coppering agent as a new treatment for Wilson disease. This is a rare genetic disorder that prevents the body from regulating copper levels and can lead to serious liver and brain damage. The product works by removing the abnormal accumulation of copper from the liver, brain and other organs. Existing treatments are inadequate and frequently have debilitating side-effects. Wilson went public in May 2016.

Location Stockholm, Sweden
CEO Jonas Hansson
Partner Genghis Lloyd-Harris
Website www.wilsontherapeutics.com